Delivery Order 75F40120D00026-75F40120F19001
- The Food and Drug Administration (FDA) awarded a $24,583,221.15 delivery order contract to The Lewin Group, Inc. (a subsidiary of UnitedHealth Group Incorporated), to support the BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS. This contract is a task order under the $50 million BEST Initiative - Data Sources for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) contract, which provides longitudinal data sources needed to...
- This is a delivery order contract awarded by the Food and Drug Administration (FDA) to The Lewin Group, Inc. for the Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics. The $14,702,547.49 contract has a period of performance through April 29, 2025 and is a Time and Materials contract type. The Lewin Group, a subsidiary of UnitedHealth Group Incorporated, will provide data sources to support the FDA's surveillance of biologics under the BEST...
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $2.9 million delivery order to International Business Machines Corporation (IBM) under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) multiple award contract. The delivery order is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics, as part of HHS FDA's BEST Initiative. Major...
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $13.2 million delivery order contract to International Business Machines Corporation (IBM) under the Biologics Effectiveness and Safety (BEST) Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract calls for IBM to provide data, tools, and infrastructure to support HHS FDA's BEST Initiative for surveillance of...
- The Department of Health and Human Services Food and Drug Administration awarded a $5,273,171.50 delivery order contract to Iqvia Government Solutions Inc. to conduct surveillance activities for the safety and effectiveness of biologics. This contract is part of the BEST Initiative, a larger indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle for data tools and infrastructure to support surveillance of biologics. Iqvia Government Solutions is a for-profit organization that has...
- This is a delivery order awarded to Iqvia Government Solutions Inc. under the Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics indefinite delivery, indefinite quantity (IDIQ) contract with the Food and Drug Administration (FDA). The $17,498,031.84 award will provide data sources to conduct surveillance of biologics, covering tens of millions of patients from insurers, payers, and providers. The BEST Initiative IDIQ is valued at $50 million and...
- This is a $4,415,338.31 delivery order contract awarded by the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) to Iqvia Government Solutions Inc., a prominent for-profit healthcare data and analytics provider. The contract is for the CBER's Biologics Effectiveness and Safety (BEST) Initiative #3, which focuses on utilizing healthcare data sources for surveillance of biologics (BEST 3). The contract is a time and materials type with a period of...
- This federal contract award was issued by the Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) to support the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative. The $8,234,421.12 delivery order contract will develop new and innovative methods for automated reporting for CBER-regulated biologics. The contract is a Time and Materials (T&M) type and does not have a set-aside designation. IBM will be...
- This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration to the International Business Machines Corporation (IBM) on September 24, 2019. The $5,622,942.08 time and materials contract is a delivery order under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics master IDIQ contract vehicle. The objective is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics. This work...
- The U.S. Department of Health and Human Services Food and Drug Administration awarded a $14,609,200.89 delivery order contract to International Business Machines Corporation (IBM) for the "DEVELOPMENT OF NEW AND INNOVATIVE METHODS FOR AUTOMATED REPORTING FOR CBER-REGULATED BIOLOGICAL PRODUCTS". This contract is a Time and Materials type under the BEST Initiative - New and Innovative Methods for Automated Reporting master IDIQ. The contract does not have a set-aside designation. IBM, as...
- 75F40120D00026Indefinite Delivery Contract
- 75F40120D00026-75F40120F19001Delivery Order
The Department of Health and Human Services Food and Drug Administration awarded a $5.1 million delivery order against the BEST Initiative - Data Sources for Surveillance of Biologics master IDIQ contract. The order is for BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS, and will be performed by The Lewin Group, Inc., doing business as Lewin Group Inc., a subsidiary of UnitedHealth Group Incorporated. Work will take place in Mosby, Virginia through September 2021. The order continues the FDA's BEST initiative by utilizing data sources to monitor the safety and effectiveness of biologics. As the prime contractor, Lewin Group will leverage its expertise in health policy research, program evaluation, and data analytics to support the FDA's post-market biologics surveillance efforts over the one year period of performance.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Close Out | ($3m) | 4/5/23 | |
| P00001 | Supplemental Agreement for work within scope | $4.4m | 7/27/21 | |
| Not listed | Not listed | $4.1m | 9/30/20 |